Our Approach

The Sementis Copenhagen Vector (SCV) system is a next-generation vaccinia viral-vector platform, engineered to be safe whilst maintaining viral potency to generate a strong and long-lasting immune response. The Company’s mission is to deliver an adaptable vaccine platform in response to rapidly emerging diseases of pandemic proportion and also to treat diseases of high unmet medical need including allergies.

Infectious Diseases

Sementis is developing a vaccine to protect against COVID-19, the biggest global health challenge of our generation. A combination vaccine to guard against Zika and chikungunya virus infection has been shown effective in advanced preclinical challenge studies.

Pandemic Preparedness

The Sementis SCV platform can be adapted to rapidly respond to emerging bio-threats. It has the potential to accelerate the development and manufacture of vaccines to combat previously unknown pathogens of pandemic proportions.

Allergies

Sementis is developing a vaccine for allergies for prophylactic and therapeutic use. Peanut allergy is one of the most common food allergies worldwide with potentially fatal consequences. Sementis has a candidate for a peanut allergy vaccine and is exploring other areas of allergy.